Present status of clinical deployment of glucokinase activators

Journal of Diabetes Investigation

Volumn 6, Issue 2, 2015, Pages 124-132

  Nakamura, Akinobu ^a   Terauchi, Yasuo ^b  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Glucokinase; Glucokinase activators; Cell proliferation

Indexed keywords

AZD 1656; CYCLIN D2; CYCLIN D3; ENZYME ACTIVATOR; GLIPIZIDE; GLUCOKINASE; GLUCOKINASE ACTIVATOR; GLUCOSE; GLUCOSE 6 PHOSPHATE; HEMOGLOBIN A1C; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; MK 0941; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PIRAGLIATIN; PLACEBO; RO 28 1675; UNCLASSIFIED DRUG;

ANTIDIABETIC ACTIVITY; APOPTOSIS; ARTICLE; CAUSE OF DEATH; CELL HYPERPLASIA; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); CNCD2 GENE; CNCD3 GENE; DIABETES MELLITUS; DNA MODIFICATION; DOSE RESPONSE; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; DYSLIPIDEMIA; ENZYME KINETICS; ENZYME METABOLISM; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME SUBSTRATE; GCK GENE; GENE; GENE MUTATION; GENETIC ASSOCIATION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLYCEMIC CONTROL; GLYCOGEN SYNTHESIS; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPOGLYCEMIA; INCIDENCE; IRS2 GENE; KETOACIDOSIS; LIPID DIET; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOGENESIS; PDPK1 GENE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION;

EID: 84923618762     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12294     Document Type: Article

References (62)

1. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet 2011; 378: 31-40.
2. Guariguata L. By the numbers: new estimates from the IDF Diabetes Atlas Update for 2012. Diabetes Res Clin Pract 2012; 98: 524-525.
3. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
4. Khan SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
5. Tahrani AA, Bailey CJ, Del Prato S, et al. Management of type 2 diabetes: new and future developments in treatment. Lancet 2011; 378: 182-197.
6. Grimsby J, Sarabu R, Corbett WL, et al. Allosteric activators of glucokinase: potential role in diabetes therapy. Science 2003; 301: 370-373.
7. Matschinsky FM. GKAs for diabetes therapy: why no clinically useful drug after two decades of trying? Trends Pharmacol Sci 2013; 34: 90-99.
8. Matschinsky FM. Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 2009; 8: 399-416.
9. Bonadonna RC, Heise T, Arbet-Engels C, et al. Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study. J Clin Endocrinol Metab 2010; 95: 5028-5036.
10. Meininger GE, Scott R, Alba M, et al. Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care 2011; 34: 2560-2566.
11. Matschinsky FM, Magnuson MA, Zelent D, et al. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes 2006; 55: 1-12.
12. Osbak KK, Colclough K, Saint-Martin C, et al. Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat 2009; 30: 1512-1526.
13. Terauchi Y, Sakura H, Yasuda K, et al. Pancreatic beta-cell-specific targeted disruption of glucokinase gene. Diabetes mellitus due to defective insulin secretion to glucose. J Biol Chem 1995; 270: 30253-30256.
14. Grupe A, Hultgren B, Ryan A, et al. Transgenic knockouts reveal a critical requirement for pancreatic beta cell glucokinase in maintaining glucose homeostasis. Cell 1995; 83: 69-78.
15. Postic C, Shiota M, Niswender KD, et al. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J Biol Chem 1999; 274: 305-315.
16. Niswender KD, Postic C, Jetton TL, et al. Cell-specific expression and regulation of a glucokinase gene locus transgene. J Biol Chem 1997; 272: 22564-22569.
17. Niswender KD, Shiota M, Postic C, et al. Effects of increased glucokinase gene copy number on glucose homeostasis and hepatic glucose metabolism. J Biol Chem 1997; 272: 22570-22575.
18. Shiota M, Postic C, Fujimoto Y, et al. Glucokinase gene locus transgenic mice are resistant to the development of obesity-induced type 2 diabetes. Diabetes 2001; 50: 622-629.
19. Velho G, Blanche H, Vaxillaire M, et al. Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families. Diabetologia 1997; 40: 217-224.
20. Steele AM, Shields BM, Wensley KJ, et al. Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. JAMA 2014; 311: 279-286.
21. Byrne MM, Sturis J, Clement K, et al. Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations. J Clin Invest 1994; 93: 1120-1130.
22. Hussain K. Mutations in pancreatic beta-cell Glucokinase as a cause of hyperinsulinaemic hypoglycaemia and neonatal diabetes mellitus. Rev Endocr Metab Disord 2010; 11: 179-183.
23. Davis EA, Cuesta-Muñoz A, Raoul M, et al. Mutants of glucokinase cause hypoglycaemia- and hyperglycaemia syndromes and their analysis illuminates fundamental quantitative concepts of glucose homeostasis. Diabetologia 1999; 42: 1175-1186.
24. Efanov AM, Barrett DG, Brenner MB, et al. A novel glucokinase activator modulates pancreatic islet and hepatocyte function. Endocrinology 2005; 146: 3696-3701.
25. Coope GJ, Atkinson AM, Allott C, et al. Predictive blood glucose lowering efficacy by Glucokinase activators in high fat fed female Zucker rats. Br J Pharmacol 2006; 149: 328-335.
26. Futamura M, Hosaka H, Kadotani A, et al. An allosteric activator of glucokinase impairs the interaction of glucokinase and glucokinase regulatory protein and regulates glucose metabolism. J Biol Chem 2006; 281: 37668-37674.
27. Fyfe MC, White JR, Taylor A, et al. Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions. Diabetologia 2007; 50: 1277-1287.
28. Gorman T, Hope DC, Brownlie R, et al. Effect of high-fat diet on glucose homeostasis and gene expression in glucokinase knockout mice. Diabetes Obes Metab 2008; 10: 885-897.
29. Nakamura A, Terauchi Y, Ohyama S, et al. Impact of small molecule glucokinase activator on glucose metabolism, beta cell function and mass. Endocrinology 2009; 150: 1147-1154.
30. Ohyama S, Takano H, Iino T, et al. A small-molecule glucokinase activator lowers blood glucose in the sulfonylurea-desensitized rat. Eur J Pharmacol 2010; 640: 250-256.
31. Nakamura A, Shimazaki H, Ohyama S, et al. Effect of long-term treatment with a small-molecule glucokinase activator on glucose metabolism, lipid profiles and hepatic function. J Diabetes Investig 2011; 2: 276-279.
32. Futamura M, Yao J, Li X, et al. Chronic treatment with a glucokinase activator delays the onset of hyperglycaemia and preserves beta cell mass in the Zucker diabetic fatty rat. Diabetologia 2012; 55: 1071-1080.
33. Lu M, Li P, Bandyopadhyay G, et al. Characterization of a novel glucokinase activator in rat and mouse models. PLoS One 2014; 9: e88431.
34. Filipski KJ, Pfefferkorn JA. A patent review of glucokinase activators and disruptors of the glucokinase-glucokinase regulatory protein interaction: 2011-2014. Expert Opin Ther Pat 2014; 24: 875-891.
35. Johnson D, Shepherd RM, Gill D, et al. Glucose-dependent modulation of insulin secretion and intracellular calcium ions by GKA50, a glucokinase activator. Diabetes 2007; 56: 1694-1702.
36. Nakamura A, Togashi Y, Orime K, et al. Control of beta cell function and proliferation in mice stimulated by small molecule glucokinase activator under various conditions. Diabetologia 2012; 55: 1745-1754.
37. Doliba NM, Qin W, Najafi H, et al. Glucokinase activation repairs defective bioenergetics of islets of Langerhans isolated from type 2 diabetics. Am J Physiol Endocrinol Metab 2012; 302: E87-E102.
38. Doliba NM, Fenner D, Zelent B, et al. Repair of diverse diabetic defects of beta-cells in man and mouse by pharmacological glucokinase activation. Diabetes Obes Metab 2012; 3: 109-119.
39. Chu CA, Fujimoto Y, Igawa K, et al. Rapid translocation of hepatic glucokinase in response to intraduodenal glucose infusion and changes in plasma glucose and insulin in conscious rats. Am J Physiol Gastrointest Liver Physiol 2004; 286: 627-634.
40. Brocklehurst KJ, Payne VA, Davies RA, et al. Stimulation of hepatocyte glucose metabolism by novel small molecule glucokinase activators. Diabetes 2004; 53: 535-541.
41. Terauchi Y, Takamoto I, Kubota N, et al. Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. J Clin Invest 2007; 117: 246-257.
42. Withers DJ, Gutierrez JS, Towery H, et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 1998; 391: 900-904.
43. Kubota N, Tobe K, Terauchi Y, et al. Disruption of insulin receptor substrate-2 causes type 2 diabetes due to liver insulin resistance and lack of compensatory β-cell hyperplasia. Diabetes 2000; 49: 1880-1889.
44. Kubota N, Terauchi Y, Tobe K, et al. Insulin receptor substrate 2 plays a crucial role in β cells and the hypothalamus. J Clin Invest 2004; 114: 917-927.
45. Kassem S, Bhandari S, Rodríguez-Bada P, et al. Large islets, beta-cell proliferation, and a glucokinase mutation. N Engl J Med 2010; 362: 1348-1350.
46. Porat S, Weinberg-Corem N, Tornovsky-Babaey S, et al. Control of pancreatic beta cell regeneration by glucose metabolism. Cell Metab 2011; 13: 440-449.
47. Oh YS, Lee YJ, Park K, et al. Treatment with glucokinase activator, YH-GKA, increases cell proliferation and decreases glucotoxic apoptosis in INS-1 cells. Eur J Pharm Sci 2014; 51: 137-145.
48. Weir GC, Bonner-Weir S. A dominant role for glucose in beta cell compensation of insulin resistance. J Clin Invest 2007; 117: 81-83.
49. Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-110.
50. Rhodes CJ. Type 2 diabetes-a matter of beta-cell life and death? Science 2005; 307: 380-384.
51. Wei P, Shi M, Barnum S, et al. Effects of glucokinase activators GKA50 and LY2121260 on proliferation and apoptosis in pancreatic INS-1 beta cells. Diabetologia 2009; 52: 2142-2150.
52. Shirakawa J, Togashi Y, Sakamoto E, et al. Glucokinase activation ameliorates ER stress-induced apoptosis in pancreatic beta-cells. Diabetes 2013; 62: 3448-3458.
53. Wilding JP, Leonsson-Zachrisson M, Wessman C, et al. Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin. Diabetes Obes Metab 2013; 15: 750-759.
54. Kiyosue A, Hayashi N, Komori H, et al. Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2013; 15: 923-930.
55. Tornovsky-Babeay S, Dadon D, Ziv O, et al. Type 2 diabetes and congenital hyperinsulinism cause DNA double-strand breaks and p53 activity in beta cells. Cell Metab 2014; 19: 109-121.
56. Pfefferkorn JA, Guzman-Perez A, Oates PJ, et al. Designing glucokinase activators with reduced hypoglycemia risk: discovery of N, N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)- carbamoyl)benzofuran-4-yloxy) pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus. MedChemComm 2011; 2: 828-839.
57. Pfefferkorn JA. Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes. Expert Opin Drug Discov 2013; 8: 319-330.
58. Erion DM, Lapworth A, Amor PA, et al. The hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats. PLoS One 2014; 9: e97139.
59. Ferre T, Riu E, Franckhauser S, et al. Long-term overexpression of glucokinase in the liver of transgenic mice leads to insulin resistance. Diabetologia 2003; 46: 1662-1668.
60. Beer NL, Tribble ND, McCulloch LJ, et al. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet 2009; 18: 4081-4088.
61. De Ceuninck F, Kargar C, Ilic C, et al. Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans. Br J Pharmacol 2013; 168: 339-353.
62. Dhanesha N, Joharapurkar A, Shah G, et al. Treatment with exendin-4 improves the antidiabetic efficacy and reverses hepatic steatosis in glucokinase activator treated db/db mice. Eur J Pharmacol 2013; 714: 188-192.